Clinical Trial

A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
Cannabidiol oral solution (CBD-OS) is approved in the US for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or Tuberous sclerosis complex (TSC) in patients 1 year of age and older. This study will assess the efficacy and safety of CBD-OS in participants aged 12 to 75 years for the treatment of focal-onset seizures (FOS).
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2025-11-14; most recent amendment 2026-06-05.
Status change: Not Yet Recruiting → Recruiting 2025-12-01
Trial Details
NCT Number NCT07233239
Lead Sponsor Jazz Pharmaceuticals
Collaborators: Jazz Pharmaceuticals Research UK Ltd.
Conditions Focal Seizures
Enrollment 100 participants
Start Date 2025-11-26
Primary Completion 2027-11-29 (estimated)
Study Completion 2027-11-29 (estimated)
Updated on ClinicalTrials.gov 2026-08-11